Distal Renal Tubular Acidosis (dRTA) Drugs Market Size, Share, Growth, Forecast and Outlook (2024-2031)

Global Distal Renal Tubular Acidosis (dRTA) Drugs Market is segmented By Type (Type 1 dRTA, Type 2 dRTA) By Drug Type (Alkali Agents, Potassium Supplements, Vitamin D Supplement, Others) By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) and By Region (North America, Europe, South America, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031

Market Overview

Global distal renal tubular acidosis (dRTA) drugs market reached US$ YY million in 2022 and is expected to reach US$ YY million by 2031, growing at a CAGR of YY% during the forecast period 2024-2031.

Distal Renal Tubular Acidosis (dRTA) is a rare disorder of the kidneys that affects their ability to eliminate acid from the body, leading to a buildup of acid in the bloodstream, which is known as metabolic acidosis. There are two primary types of dRTA: Type 1 and Type 2. In Type 1 dRTA, the distal tubules of the kidneys are unable to secrete hydrogen ions into the urine, which can result in low levels of potassium in the blood (hypokalemia). In Type 2 dRTA, there is impaired reabsorption of bicarbonate in the proximal tubules of the kidneys.

The goal of treatment for acid-base imbalances is to manage them effectively. This can be achieved through medication, such as potassium citrate and sodium bicarbonate, potassium supplements, and diuretics like hydrochlorothiazide for Type 1 dRTA. In cases of secondary dRTA, it is also important to address underlying causes. It is crucial to regularly monitor the use of these medications to ensure their effectiveness and safety in managing this condition.

Market Scope

For more details on this report – Request for Sample

Market Dynamics: Drivers and Restraints 

The increasing clinical trials of drugs are expected to drive the market growth

ADV7103 is an investigational drug designed to treat distal renal tubular acidosis (dRTA) in both children and adults. dRTA can have either a genetic origin, also known as primary dRTA, or be acquired as a result of autoimmune disorders or other conditions. While the inherited form of dRTA is most common among infants and children, the acquired form is more prevalent in adults

The lead product ADV7103 is currently approved for the treatment of distal renal tubular acidosis (dRTA) in Europe and entering the PIII development phase in the United States. This product is also under development for Cystinuria in both Europe and the United States. Advicenne aims to develop a strong, valuable, and sustainable portfolio of products that cater to the unmet requirements of rare renal diseases.

Therefore, advancements in pharmaceutical research, including the development of drugs like ADV7103, can help address unmet medical needs and provide hope for better outcomes for those with rare medical conditions.

Furthermore, growing awareness about rare renal diseases among the general public, and collaborations between pharmaceutical companies and research institutions are the other factors expected to drive the market over the forecast period.

Restraint:

Fewer treatment options and limited research funding can pose challenges for drug development in identifying effective treatment targets due to the complex mechanisms underlying dRTA are the factors expected to hamper the market over the forecast period.

Segment Analysis

The global distal renal tubular acidosis (dRTA) drugs market is segmented based on type, drug type, distribution channel and region.

The alkali agents from the drug type segment accounted for approximately 43.2% of the distal renal tubular acidosis (dRTA) drugs market share

Distal Renal Tubular Acidosis (dRTA) is a rare kidney disorder where the kidneys are unable to excrete acid into the urine, leading to metabolic acidosis. Alkali agents, like potassium citrate and sodium bicarbonate, play a crucial role in the treatment strategy for this condition. These agents help to raise urine pH and neutralize the excessive acid buildup in the blood.

Using alkali agents to treat dRTA comes with several advantages. These agents can correct acid-base imbalances, prevent electrolyte abnormalities, and improve the overall health and well-being of affected individuals. They are effective in mitigating the symptoms and complications associated with dRTA, such as muscle weakness, bone disease, and growth issues in children.

Factors expected to drive the market for alkali agents in dRTA treatment include the increasing awareness of rare renal diseases and growing recognition of unmet medical needs in this field. Additionally, the market for treating dRTA is likely to expand due to the differentiation between primary and acquired dRTA. As research progresses and more effective treatments become available, the outlook for individuals with dRTA is expected to improve, further stimulating the market's growth.

For instance, the National Kidney Foundation launched a website to raise awareness and educate patients and their families about Distal Renal Tubular Acidosis (dRTA). The website provides comprehensive information on dRTA's symptoms, diagnosis, and treatment options. It also offers helpful resources for patients and their families to gain a better understanding of the disease and learn how to manage it effectively. The website's primary aim is to assist patients and their families in comprehending dRTA and its impact on their lives, making it a valuable resource for those living with the disease or caring for someone who does.

Geographical Analysis

North America accounted for approximately 42.5% of the market share in 2022

North America is expected to hold the largest market share, owing to the increasing clinical trials of drugs, and increasing prevalence of dRTA.

For instance, the progress of ADV7103 through Phase 2/3 trials in the United States is a significant advancement in addressing the unmet medical needs of patients with dRTA. This has the potential to expand the market, enhance treatment options, and improve the overall outlook for individuals living with dRTA. With continued research and development, the dRTA drug market is expected to evolve, bringing advancements that would benefit both patients and the pharmaceutical industry.

Additionally, approximately 30,000 patients in Europe and 20,000 in the United States are affected by dRTA, whether genetically or as a result of an immune disease. Hence, owing to the above factors, the North America is expected to hold the largest market share over the forecast period.

COVID-19 Impact Analysis

The COVID-19 pandemic had a significant impact on the market for drugs used to treat distal renal tubular acidosis (dRTA). The disruptions in global supply chains caused by the pandemic potentially affected the production and distribution of medications for rare diseases like dRTA. The healthcare sector's shift towards managing the pandemic strained resources, leading to possible delays in the diagnosis and treatment of rare conditions like dRTA.

Moreover, the clinical trials for new dRTA drugs were affected, causing delays in drug development and approval processes. Economic uncertainties may have affected patients' ability to afford medications, potentially impacting the demand for drugs in the market. 

In addition, the limited access to healthcare facilities may have led to delayed diagnosis and treatment for dRTA patients, which could have affected both patient outcomes and market dynamics. These factors demonstrate how the pandemic has moderately influenced the market for dRTA drugs.

Competitive Landscape

The major global players in the distal renal tubular acidosis (dRTA) drugs market include Pfizer, Inc., Bell's Healthcare, Upsher-Smith Laboratories, LLC, Advicenne, Teva Pharmaceuticals USA, Inc., sanofi-aventis US LLC, AbbVie Inc., and Strides Pharma Science Limited among others.

Key Development

• On July 2, 2021, Advicenne is a pharmaceutical company that specializes in developing and selling innovative treatments for rare renal diseases. The company announced that the Medicines & Healthcare Products Regulatory Agency (MHRA) has granted market authorization for Sibnayal (ADV7103) in the UK. This drug is intended for the treatment of distal renal tubular acidosis (dRTA).

Why Purchase the Report?

• To visualize the global distal renal tubular acidosis drugs market segmentation based on type, drug type, distribution channel and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development. 
• Excel data sheet with numerous data points of distal renal tubular acidosis drugs market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global distal renal tubular acidosis drugs market report would provide approximately 55 tables, 55 figures, and 189 Pages.

Target Audience 2024

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies